Altimmune (ALT) Profit After Tax (2010 - 2026)

Altimmune (ALT) has reported Profit After Tax for 17 consecutive years, with -$22.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax fell 16.6% year-over-year to -$22.9 million; the TTM figure through Mar 2026 stood at -$91.4 million (down 1.26% YoY), while the FY2025 annual figure was -$88.1 million, up 7.3% from the prior year.
• Profit After Tax climbed to -$22.9 million in Q1 2026 per ALT's latest filing, from -$27.4 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$16.1 million in Q2 2023 and bottomed at -$31.6 million in Q4 2023.
• Historically, Profit After Tax has averaged -$22.3 million across 5 years, with a median of -$22.1 million in 2025.
• Annual changes were most pronounced in 2022 — Profit After Tax increased 29.4% — and 2024, when it slumped 53.42%.
• Altimmune's Profit After Tax stood at -$21.7 million in 2022, then plunged by 46.08% to -$31.6 million in 2023, then climbed by 26.84% to -$23.1 million in 2024, then declined by 18.18% to -$27.4 million in 2025, then increased by 16.44% to -$22.9 million in 2026.
• Business Quant data shows ALT's Profit After Tax at -$22.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$19.0 million in Q3 2025.